Expert Center for cardiac amyloidosis: reality and perspectives

封面

如何引用文章

全文:

详细

Aim. To evaluate the features of diagnosis of amyloid cardiomyopathy (ACMP), differential diagnosis of different types of amyloidosis and its clinical manifestations.

Materials and methods. Were analyzed 150 cases of patients who consulted at the Expert Center for Amyloidosis with suspicion of the presence of ACMP. 63 patients were diagnosed with ACMP: 25 (39.7%) – women, 38 (60.3%) – men, with an average age of 64.1±1.5. 36 (57.1%) patients had AL-amyloidosis (immunoglobulin amyloid light-chain amyloidosis), 25 (39.7%) – ATTR-amyloidosis (transthyretin amyloidosis), 2 (3.2%) – AA-amyloidosis with heart failure (reactive systemic amyloidosis caused by hypersecretion of á-globulin). The analysis of clinical manifestations depending on the type of amyloidosis, data of laboratory and instrumental methods of diagnosis is carried out.

Results. In most cases, 53 (84.1%) patients, amyloidosis manifested as signs of heart failure. Among cardiac manifestations, shortness of breath (95.2%), general weakness (93.7%), lower limb edema (76.2%) were the most common. To confirm the diagnosis, despite the high accuracy of the speckle-tracking echocardiography and magnetic resonance imaging of the heart with gadolinium, in rare cases a biopsy is required (e.g. there is a combination of clinical signs of several types of amyloidosis). Biopsy of the affected organ was performed in 31 (49.2%) patients. The strategy for further pathogenetic treatment depends on the determination of the type of amyloidosis. Free light chains of immunoglobulins were detected in 57.1% of cases, which allowed diagnosis of AL-amyloidosis. In 17 (38.6%) patients myocardial scintigraphy with 99mTc-pyrophosphate showed signs of ATTR-amyloidosis, which with a negative result of immunochemical studies allows non-invasive diagnosis of it.

Conclusion. ACMP is a disease with an extremely adverse prognosis. Raising the awareness of specialists about ACMP is an important goal. With timely diagnosis, pathogenetic therapy can be started early, which will improve the quality of life and prognosis of patients with ACMP.

作者简介

Svetlana Nasonova

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-0920-7417

канд. мед. наук, ст. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности

俄罗斯联邦, Moscow

Igor Zhirov

Chazov National Medical Research Center of Cardiology

编辑信件的主要联系方式.
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4066-2661

д-р мед. наук, вед. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности

俄罗斯联邦, Moscow

Anastasiya Shoshina

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-9519-7373

аспирант отд. заболеваний миокарда и сердечной недостаточности

俄罗斯联邦, Moscow

Yulia Osmolovskaya

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-7827-2618

канд. мед. наук, науч. сотр. отд. заболеваний миокарда и сердечной недостаточности

俄罗斯联邦, Moscow

Alexey Ansheles

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-2675-3276

д-р мед. наук, вед. науч. сотр. отд. радионуклидной диагностики и позитронно-эмиссионной томографии

俄罗斯联邦, Moscow

Olga Tchaikovskaya

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-2251-1675

врач функциональной диагностики отд-ния ультразвуковой диагностики

俄罗斯联邦, Moscow

Svetlana Dobrovolskaya

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0003-0580-393X

канд. мед. наук, мл. науч. сотр. отд. ультразвуковых методов исследования

俄罗斯联邦, Moscow

Vladimir Sergienko

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-0487-6902

д-р мед. наук, проф., рук. отд. радионуклидной диагностики и позитронно-эмиссионной томографии

俄罗斯联邦, Moscow

Marina Saidova

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0002-3233-1862

д-р мед. наук, проф., рук. отд. ультразвуковых методов исследования

俄罗斯联邦, Moscow

Sergey Tereshchenko

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0001-9234-6129

д-р мед. наук, проф., рук. отд. заболеваний миокарда и сердечной недостаточности

俄罗斯联邦, Moscow

Sergey Boytsov

Chazov National Medical Research Center of Cardiology

Email: izhirov@mail.ru
ORCID iD: 0000-0001-6998-8406

акад. РАН, д-р мед. наук, проф., ген. дир.

俄罗斯联邦, Moscow

参考

  1. Bajwa F, O'Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev. 2022;27(5):1471-84. doi: 10.1007/s10741-021-10162-1
  2. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915
  3. Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268-92. doi: 10.1111/joim.13169
  4. Chen A, Chen YM. Donepezil, a potential therapeutic agent for heart failure. Eur J Heart Fail. 2015;17(2):233. doi: 10.1002/ejhf.214
  5. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18(Suppl. 2):s30-5. doi: 10.7861/clinmedicine.18-2-s30
  6. Gertz MA. Cardiac Amyloidosis. Heart Fail Clin. 2022;18(3):479-88. doi: 10.1016/j.hfc.2022.02.005
  7. Vaxman I, Gertz M. When to Suspect a Diagnosis of Amyloidosis. Acta Haematol. 2020;143(4):304-11. doi: 10.1159/000506617
  8. Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72(17):2040-50. doi: 10.1016/j.jacc.2018.07.092
  9. Gilstrap L, Dominici F, Wang Y, et al. Epidemiology of Cardiac Amyloidosis Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407. doi: 10.1161/CIRCHEARTFAILURE.118.005407
  10. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. doi: 10.1136/heartjnl-2012-302353
  11. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013;26(2):185-91. doi: 10.1016/j.echo.2012.10.008
  12. Roger-Rollé A, Cariou E, Rguez K, et al. Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart. 2020;7(2). doi: 10.1136/openhrt-2020-001346
  13. Clemmensen TS, Eiskjær H, Ladefoged B, et al. Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021;22(6):695-704. doi: 10.1093/ehjci/jeaa097
  14. Giblin GT, Cuddy SAM, González-López E, et al. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2022;23(8):1029-39. doi: 10.1093/ehjci/jeac049
  15. Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109(1):78-88. doi: 10.1007/s00392-019-01490-2
  16. Palmiero G, Rubino M, Monda E, et al. Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis. J Cardiovasc Echogr. 2021;31(3):157-64. doi: 10.4103/jcecho.jcecho_16_21
  17. Nativi-Nicolau J, Sarswat N, Fajardo J, et al. Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates. Clin Med Insights Cardiol. 2021;15:11795468211015230. doi: 10.1177/11795468211015230
  18. Рамеев В.В., Мясников Р.П., Виноградов П.П., и др. Системный ATTR-амилоидоз, редкая форма поражения внутренних органов. Рациональная Фармакотерапия в Кардиологии. 2019;15(3):349-58 [Rameev VV, Myasnikov RP, Vinogradov PP, et al. Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage. Rational Pharmacotherapy in Cardiology. 2019;15(3):349-58 (in Russian)]. doi: 10.20996/1819-6446-2019-15-3-349-358
  19. Рамеев В.В., Козловская Л.В., Рамеева А.С., и др. Особенности эволюции и прогностическое значение поражения сердца у больных системным AL-амилоидозом. Клиническая фармакология и терапия. 2019;28(2):49-56 [Rameev VV, Kozlovskaya LV, Rameeva AS, et al. Evolution and prognostic significance of heart involvement in patients with systemic AL-amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2019;28(2):49-56 (in Russian)]. doi: 10.32756/0869-5490-2019-2-49-56
  20. Резник Е.В., Степанова Е.А., Нгуен Т.Л., и др. Ретроспективный анализ поражения сердечно-сосудистой системы у больных системным амилоидозом. Кардиоваскулярная терапия и профилактика. 2021;20(1):2496 [Reznik EV, Stepanova EA, Nguyen TL, et al. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021;20(1):2496 (in Russian). doi: 10.15829/1728-8800-2021-2496
  21. Nativi-Nicolau J, Fine NM, Ortiz-Pérez JT, et al. Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis. J Comp Eff Res. 2022;11(14):1031-44. doi: 10.2217/cer-2022-0074
  22. Kyrouac D, Schiffer W, Lennep B, et al. Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing. ESC Heart Fail. 2022;9(1):385-97. doi: 10.1002/ehf2.13738
  23. Wisniowski B, Wechalekar A. Confirming the Diagnosis of Amyloidosis. Acta Haematol. 2020;143(4):312-21. doi: 10.1159/000508022
  24. Panagiotopoulos I, Papatheodorou E, Anastasakis A, et al. Transthyretin (Pro24Ser) variant amyloidosis: A case report of the first patient in Greece. Hell J Nucl Med. 2023;26(2):145-9.

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. The most common echocardiogram phenotypes in patients with AC, %.

下载 (63KB)
3. Fig. 2. Typical pattern of speckle tracking echocardiography in AC.

下载 (108KB)
4. Fig. 3. Correlation of the risk of major adverse cardiovascular events (МАСЕ) with the parameters of myocardial function [13].

下载 (198KB)
5. Fig. 4. Pattern of speckle tracking echocardiography and myocardial function in AC of patient K. with AL-amyloidosis: a – before therapy; b – 1 year after therapy.

下载 (162KB)

版权所有 © Consilium Medicum, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 
 


##common.cookie##